The data protection provisions in the USMCA are looking at an extension of the protection for biologic medicine, a specific class of medicines, for an additional two years. It's all fairly new to all of us. We are currently in the process of going through the text and trying to get an understanding of it. We know that intellectual property is the foundation of our ecosystem being able to innovate, but we also know that data protection has a very long time frame, so we're looking eight to 10 years out.
We will continue to work with the provincial governments and all public payers, federal and provincial, to negotiate fair prices for our pharmaceuticals through the mechanism that exists today of the pan-Canadian pharmaceutical alliance. We will ensure that the medicines and the prices of our pharmaceuticals remain fair through the process that exists.